Molotinib (Ojjaara) use restrictions and high-risk groups

Molotinib, a new kinase inhibitor drug developed by GlaxoSmithKline, provides a new treatment approach for patients with myelofibrosis. However, as with all drugs, their use is not unlimited and use in certain groups may require special caution or avoidance. The following is a detailed explanation of the contraindications and high-risk users of molotinib.

1. Taboos on use

Its use must be strictly prohibited in patients with an allergic reaction to molotinib or any of its ingredients. Allergic reactions can cause serious symptoms such as skin rash, difficulty breathing, and body swelling, and sometimes can even be life-threatening.

2. High-risk user groups

1. Patients with impaired liver function: Molotinib may exacerbate the patient's increase in ALT, AST and bilirubin, so patients with impaired liver function should be particularly careful. This drug should be used with caution, especially in patients with severe hepatic impairment (eg, Child-Pugh class C). Because their liver function is reduced, they may not be able to metabolize and excrete medications efficiently, increasing their risk of side effects. Before and during medication, doctors need to regularly monitor the liver enzyme indicators of such patients to ensure the safety of medication.

2. Patients with chronic hepatitis B virus infection: Molotinib may increase the viral load in these patients. Therefore, doctors need to obtain the patient's hepatitis B-related serological data before initiating treatment. For patients who are HBsAg positive or total anti-HBc positive, consultation with liver-related experts should be considered for necessary monitoring or preventive treatment.

3. Patients with active infections: Because molotinib may increase the risk of serious or even fatal infections, doctors should conduct a comprehensive assessment of the patient’s infection status before and during treatment. Doctors should avoid using this drug or use it with extreme caution if the patient has an existing infection.

4. With a history of malignancy or smokers: Cases of malignant tumors (including lymphoma and solid tumors) have been reported in patients taking otherJAK inhibitors. Therefore, physicians should pay special attention to the use of molotinib in patients with current or past smoking history and in patients with known malignancy (other than successfully treated non-melanoma skin cancer).

5. Women of childbearing age: Molotinib may pose a potential threat to the fetus. Therefore, female patients receiving treatment should take reliable contraceptive measures during treatment and within one week after stopping treatment. If the patient is pregnant or suspected to be pregnant, the health care provider should be notified immediately.

In summary, molotinib has brought a new treatment method to patients with myelofibrosis, but when using it, the above contraindications and usage guidance for high-risk groups must be strictly followed to ensure patient safety. Doctors should develop the most appropriate treatment plan for patients based on their individual circumstances.